1652 — Fusen Pharmaceutical Share News
0.000.00%
Last trade - 00:00- HK$584.05m
- HK$848.02m
- CNY273.37m
Brief: Fusen Pharmaceutical Says Application For Launching Measartan Potassium Tablets Accepted By NMPA
Brief: Fusen Pharmaceutical Sees Loss Attributable RMB30 Mln To RMB45 Mln
Brief: Fusen Pharmaceutical Says Application For Launching `Doxazosin Mesylate Extended-Release Tablets Accepted
Brief: Fusen Pharmaceutical Says Application For Launching Enzalutamide Soft Capsules Accepted By Nmpa
Brief: Fusen Pharmaceutical Says Compound Potassium Phosphate Injection Accepted By NMPA
Brief: Fusen Pharmaceutical Says Subscription Of Interest In Limited Liability Partnership
Brief: Fusen Pharmaceutical Says Application For Launching ``Metformin Empagliflozin Tablets (I)'' Accepted By NMPA
Brief: Fusen Pharmaceutical Sees Loss Attributable With A Range From RMB35 Mln To RMB43 Mln For FY
Brief: Fusen Pharmaceutical Sees Profit Attributable RMB10 Million To RMB25 Million For Six Months
Brief: Fusen Pharmaceutical Co Sees FY2022 Loss Attributable Between RMB30 Mln To RMB40 Mln
Brief: HKEX Announces Disciplinary Action Against Fusen Pharmaceutical & Five Current Directors
Brief: Fusen Pharmaceutical Says HY Revenue RMB165.6 Mln
Brief: Fusen Pharmaceutical Co Ltd Sees Loss Attributable With A Range From Rmb5 Million To Rmb9 Million For Six Months
Brief: Fusen Pharmaceutical And Taumedika Srl Enter Into Distribution Agreement
Brief: Fusen Pharmaceutical Resolved To Issue 5 Million New Shares Under General Mandate
Brief: Fusen Pharmaceutical Says Trading In Shares Halted On 30 May
Brief: Fusen Pharmaceutical Says Co, Dermaqual Sarl Entered Distribution Deal
Brief: Fusen Pharmaceutical Company Ltd Expects To Record Profit Attributable Of RMB63 Mln To RMB75 Mln For Year
Brief: Fusen Pharma Updates Regarding A Licence Agreement